Alumis (ALMS) Tax Provisions (2024 - 2026)
Alumis (ALMS) posted quarterly Tax Provisions of -$39000.0 for Q4 2025, up 99.94% year-over-year from -$19506.2 in Q4 2024, and up 99.54% quarter-over-quarter from -$8.6 million in Q2 2025.
Powered by 
Analysis
Alumis (ALMS) Tax Provisions (2024 - 2026) Analysis & Trends
Alumis (ALMS) has reported Tax Provisions for 2 consecutive years, with -$39000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Tax Provisions rose 99.94% year-over-year to -$39000.0; the TTM figure through Dec 2025 stood at -$70.4 million (changed N/A YoY), while the FY2025 annual figure was -$8.6 million, up 86.08% from the prior year.
- Tax Provisions climbed to -$39000.0 in Q4 2025 per ALMS's latest filing, from -$8.6 million in the prior quarter.
- Across five years, Tax Provisions topped out at -$39000.0 in Q4 2025 and bottomed at -$61.8 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Alumis | 1.43 Bn | 924.11 Mn | - | -1.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.80 Mn |
| Dec 31, 2025 | -44.30 Mn |
| Jun 30, 2025 | -8.60 Mn |
| Dec 31, 2024 | -61.79 Mn |